#Synapses

In a groundbreaking development that could reshape Alzheimer’s diagnosis and treatment, researchers are introducing new lab tests that prioritize the detection of cognitive decline over the presence of brain plaques traditionally associated with Alzheimer’s disease. This novel approach stems from the realization that the presence of amyloid plaques, historically a diagnostic hallmark, does not necessarily correlate with memory loss or dementia. The new tests instead focus on biomarkers that directly indicate cognitive impairment, potentially offering a more accurate assessment of Alzheimer’s progression.